Advertisement
Advertisement
XERS
Xeris Biopharma Holdings, Inc. Common Stock
6.38
USDSponsored
+0.15
+2.41%
May 21, 15:59 UTC -4
Closed
After-Market
6.62
+0.24
+3.76%
XERS Earnings Reports
Positive Surprise Ratio
XERS beat 18 of 32 last estimates.
56%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$92.23M
/$0.01
Implied change from Q1 26 (Revenue/ EPS)
+10.95%
/--
Implied change from Q2 25 (Revenue/ EPS)
+28.93%
/-200.00%
Xeris Biopharma Holdings, Inc. Common Stock earnings per share and revenue
On May 07, 2026, XERS reported earnings of 0.01 USD per share (EPS) for Q1 26, beating the estimate of 0.00 USD, resulting in a 217.65% surprise. Revenue reached 83.13 million, compared to an expected 81.59 million, with a 1.88% difference. The market reacted with a +4.08% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of 0.01 USD, with revenue projected to reach 92.23 million USD, implying an increase of 0.00% EPS, and increase of 10.95% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ARS Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.61
Surprise
-13.81%
ProKidney Corp. Class A Ordinary Shares
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+0.57%
Galectin Therapeutics Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.08
Surprise
-30.72%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
$0.29
Actual
-$0.04
Surprise
-113.64%
Incannex Healthcare Limited - ADR
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.94
Actual
-$11.22
Surprise
-1088.38%
VYNE Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.08
Surprise
+56.43%
Wellgistics Health, Inc. Common Stock
Report Date
May 19, 2026 For Q1 26
Estimate
-Actual
-$0.07
Surprise
-
Traws Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.75
Actual
-$0.53
Surprise
+29.78%
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.77
Actual
-$1.28
Surprise
-65.12%
AIM ImmunoTech Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.37
Actual
-$0.56
Surprise
-52.53%
FAQ
What were Xeris Biopharma Holdings, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Xeris Biopharma Holdings, Inc. Common Stock reported EPS of $0.01, beating estimates by 217.65%, and revenue of $83.13M, 1.88% above expectations.
How did the market react to Xeris Biopharma Holdings, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 4.08%, changed from $6.37 before the earnings release to $6.63 the day after.
When is Xeris Biopharma Holdings, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Xeris Biopharma Holdings, Inc. Common Stock's next earnings report?
Based on 6
analysts, Xeris Biopharma Holdings, Inc. Common Stock is expected to report EPS of $0.01 and revenue of $92.23M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement